Adding Tafasitamab to Lenalidomide and Rituximab Prolongs PFS in Patients with Relapsed or Refractory Follicular Lymphoma By Ogkologos - December 18, 2025 437 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the inMIND study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Why Cancer Survivors Should Have a Written Survivorship Care Plan March 9, 2021 How Having a Creative Outlet Helped Me Cope During Cancer November 8, 2022 Use of Immune Checkpoint Inhibitors is Safe and Effective in Patients... May 26, 2023 ‘Being open will help bring awareness’: Meet the fashion vlogger who... November 16, 2022 Load more HOT NEWS Plasma Lipid Biomarker PCPro Associated with Shorter OS and Earlier Clinical... Stiff “Hot Spots” Within Tumors Help Doctors Predict Spread of Breast... First-Line Pembrolizumab Continues to Show Durable Clinical Benefit After 5 Years... Combining Daratumumab with VRd Improves Outcomes in Patients with Transplant-Ineligible or...
